Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#1590 Treatment of Metastatic Pancreatic Neuroendocrine Tumors: Relevance of ENETS 2016 Guidelines

Introduction: The choice of first-line treatment of metastatic pancreatic neuroendocrine tumors (mP-NET) is mainly based on prognostic factors. ENETS-2016 guidelines proposed treatments according to 3 groups: Group-1, patients in whom all lesions could be removed; Group-2, patients with Ki6710% or significant tumor burden or progressive disease, for whom a systemic chemotherapy is proposed

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Foulfoin M

Authors: Foulfoin F, Graillot E, Adham M, Rousset P, Forestier J,

Keywords: pancreas, metastasis,

#1096 How Manage Multiple Small Bowel Neuroendocrine Tumors?

Introduction: Multiple small bowel neuroendocrine tumors (SB-NET) represent 30% of SB-NET.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Pasquet A

Authors: Pasquer A, Walter T, Hervieu V, Forestier J, Scoazec J,

Keywords: small bowel, surgery, prognosis, multiple,

#1067 Gemox or Alkylating Agents in Neuroendocrine Tumors? The Help of O6-Methylguanine-DNA Methyltransferase (MGMT) Status?

Introduction: Alkylating agents are the backbone chemotherapy in neuroendocrine tumors (NET). However, gemcitabine associated to oxaliplatine (gemox) has showed interesting activity in a small study.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Dussol A, Joly M, Hervieu V, Forestier J, Lombard-Bohas C,

Keywords: gemox, alkylating agent, MGMT,

#748 O6-Methylguanine-DNA Methyltransferase Deficiency in Neuroendocrine Tumors and Correlation with Response to Alkylating Agents (Temozolomide, Streptozotocin, Dacarbazine)

Introduction: Low O6-methylguanine-DNA methyltransferase (MGMT) expression is predictive of response to alkylants in some tumor types.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Van Brakel B, Walter T, Hervieu V, Forestier J, Chayvialle J,

Keywords: MGMT,